Mizuho Begins Coverage on Envista (NYSE:NVST)

Mizuho began coverage on shares of Envista (NYSE:NVST) in a research report report published on Wednesday morning, MarketBeat reports. The brokerage issued an underperform rating and a $20.00 price objective on the stock.

Other equities research analysts also recently issued reports about the company. Leerink Partnrs raised Envista from a “strong sell” rating to a “hold” rating in a report on Thursday, October 31st. Wells Fargo & Company started coverage on Envista in a report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price target on the stock. JPMorgan Chase & Co. downgraded Envista from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $23.00 to $16.00 in a report on Thursday, August 8th. Robert W. Baird upped their price target on Envista from $17.00 to $22.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. Finally, Bank of America lowered their price target on Envista from $22.00 to $19.00 and set a “buy” rating on the stock in a report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $20.65.

Envista Trading Down 6.5 %

Envista stock opened at $20.57 on Wednesday. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. The business’s fifty day simple moving average is $19.96 and its two-hundred day simple moving average is $18.34. Envista has a 12 month low of $15.15 and a 12 month high of $25.64. The company has a market capitalization of $3.54 billion, a price-to-earnings ratio of -2.65, a price-to-earnings-growth ratio of 3.10 and a beta of 1.31.

Envista (NYSE:NVST) last released its earnings results on Wednesday, October 30th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The business had revenue of $601.00 million for the quarter, compared to the consensus estimate of $590.34 million. During the same period in the previous year, the company posted $0.43 earnings per share. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year. As a group, equities analysts predict that Envista will post 0.72 earnings per share for the current fiscal year.

Institutional Trading of Envista

A number of hedge funds have recently bought and sold shares of the company. M&G Plc increased its position in Envista by 12.5% in the second quarter. M&G Plc now owns 306,253 shares of the company’s stock worth $5,206,000 after buying an additional 33,923 shares in the last quarter. Nuance Investments LLC increased its position in Envista by 47.2% in the second quarter. Nuance Investments LLC now owns 7,038,313 shares of the company’s stock worth $117,048,000 after buying an additional 2,256,993 shares in the last quarter. Sei Investments Co. increased its position in Envista by 20.4% in the second quarter. Sei Investments Co. now owns 925,170 shares of the company’s stock worth $15,386,000 after buying an additional 157,048 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in Envista in the second quarter worth about $7,019,000. Finally, Raymond James & Associates increased its position in Envista by 22.6% in the second quarter. Raymond James & Associates now owns 1,032,350 shares of the company’s stock worth $17,168,000 after buying an additional 190,240 shares in the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.